{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:47:41Z","timestamp":1787500061834,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>It is known that one of the reasons for the increased incidence of hematological malignancies is caused by the growth of multiple myeloma (MM). Worldwide, approximately 159,985 new cases of MM are diagnosed representing 0.9% of all cancer diagnoses and 106,105 patients will die from MM accounting for 1.1% of all cancer deaths per year. Despite significant advances in the MM treatment the mortality rates are still high. The presented study is the first accurate epidemiological study of \u041c\u041c in Armenia for the period of 2006\u20132018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The initial data for this retrospective cohort survey were derived from ambulance cards, hospitalization journals, and clinical data from the Registry of Blood Diseases at the Yeolyan Hematology Center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data analysis showed that during 2006\u20132018 the average annual incidence for the MM was 1.2 per 100,000 population. A significant increase was observed in 2018 compared to 2006, 1.9 vs. 0.7 per 100,000 population. Interestingly, there were no sex differences in the overall MM incidence during the study period.<\/jats:p>\n                    <jats:p>According to the received data, during the period of the 2006\u20132009 and 2014\u20132018 the 1-year survival rate for both sexes decreased dramatically from 83 to 64.1% at age group 60\u2009years and below and from 78.5 to 68.1% in group 60\u2009years and over. The 1-year overall survival (OS) for both sexes decreased by 18.9% for patients (\u226460 age group) and 10.4% (&gt;\u200960 age group) in the period of 2006\u20132009 to the period of 2014\u20132018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The incidence rates for the MM increased during the analyzed period. Our study showed that males and females in the age group 60\u2009years and below had better 5-year overall survival compared to elder ones and females have better survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08676-w","type":"journal-article","created":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T06:02:56Z","timestamp":1629525776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multiple myeloma in Armenia during the period 2006\u20132018: facts and discussion"],"prefix":"10.1186","volume":"21","author":[{"given":"Narine","family":"Ghazaryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samvel","family":"Danelyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samvel","family":"Bardakhchyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahit","family":"Saharyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lusine","family":"Sahakyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,21]]},"reference":[{"key":"8676_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.canep.2018.01.015","volume":"53","author":"\u041c Andres","year":"2018","unstructured":"Andres \u041c, Feller \u0410, Arndt V. Trends of incidence, mortality, and survival of multiple myeloma in Switzerland between 1994 and 2013. Cancer Epidemiol. 2018;53:105\u201310. https:\/\/doi.org\/10.1016\/j.canep.2018.01.015.","journal-title":"Cancer Epidemiol"},{"key":"8676_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.canep.2019.02.010","volume":"59","author":"K Bora","year":"2019","unstructured":"Bora K. Distribution of multiple myeloma in India: heterogeneity in incidence across age, sex and geography. Cancer Epidemiol. 2019;59:215\u201320.","journal-title":"Cancer Epidemiol"},{"issue":"4","key":"8676_CR3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","volume":"1","author":"LJ Costa","year":"2017","unstructured":"Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017;1(4):282\u20137. https:\/\/doi.org\/10.1182\/bloodadvances.2016002493.","journal-title":"Blood Adv"},{"issue":"9","key":"8676_CR4","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2128.","journal-title":"JAMA Oncol"},{"key":"8676_CR5","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1200\/JCO.2016.68.3805","volume":"35","author":"RS Go","year":"2017","unstructured":"Go RS, Bartley AC, Crowson CS, et al. Association between treatment facility volume and mortality of patients with multiple myeloma. J Clin Oncol. 2017;35:598\u2013604.","journal-title":"J Clin Oncol"},{"key":"8676_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.19.11000","volume":"5","author":"V Hungria","year":"2019","unstructured":"Hungria V, Chiattone C, Pavlovsky M, et al. Epidemiology of hematologic malignancies in real-world settings: findings from the Hemato-oncology Latin America observational registry study. J Glob Oncol. 2019;5:1\u201319.","journal-title":"J Glob Oncol"},{"key":"8676_CR7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International Myeloma Working Group","year":"2003","unstructured":"International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749\u201357.","journal-title":"Br J Haematol"},{"issue":"6","key":"8676_CR8","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676\u201381.","journal-title":"Semin Oncol"},{"issue":"7","key":"8676_CR9","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ajh.23731","volume":"89","author":"K Kim","year":"2014","unstructured":"Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, et al. Clinical profiles of multiple myeloma in Asia-an Asian myeloma network study. Am J Hematol. 2014;89(7):751\u20136. https:\/\/doi.org\/10.1002\/ajh.23731.","journal-title":"Am J Hematol"},{"issue":"6","key":"8676_CR10","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/leu.2014.23","volume":"28","author":"SY Kristinsson","year":"2014","unstructured":"Kristinsson SY, Anderson WF, Landgren O. Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia. 2014;28(6):1346\u20138. https:\/\/doi.org\/10.1038\/leu.2014.23.","journal-title":"Leukemia."},{"issue":"11","key":"8676_CR11","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1002\/cncr.20652","volume":"101","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ. Incidence of multiple myeloma in Olmsted County, Minnesota-trend over 6 decades. Cancer. 2004;101(11):2667\u201374. https:\/\/doi.org\/10.1002\/cncr.20652.","journal-title":"Cancer."},{"issue":"1","key":"8676_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-019-0807-5","volume":"12","author":"J Liu","year":"2019","unstructured":"Liu J, Liu W, et al. Incidence and mortality of multiple myeloma in China, 2006\u20132016: an analysis of the global burden of disease study. J Hematol Oncol. 2019;12(1):136\u201342. https:\/\/doi.org\/10.1186\/s13045-019-0807-5.","journal-title":"J Hematol Oncol"},{"key":"8676_CR13","unstructured":"Myeloma incidence statistics. 2015 UK CR. http:\/\/www.cancerresearchuk.org\/cancer-info\/cancerstats\/types\/myeloma\/incidence\/uk-multiple-myeloma-incidence-statistics."},{"issue":"17","key":"8676_CR14","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.2008.20.8983","volume":"27","author":"BD Smith","year":"2009","unstructured":"Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758\u201365. https:\/\/doi.org\/10.1200\/JCO.2008.20.8983.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8676_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3322\/caac.21499","volume":"69","author":"H Sung","year":"2019","unstructured":"Sung H, Siegel RL, Torre LA, Siegel RL, Torre LA, Pearson-Stuttard J, et al. Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin. 2019;69(2):88\u2013112. https:\/\/doi.org\/10.3322\/caac.21499.","journal-title":"CA Cancer J Clin"},{"key":"8676_CR16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(13)70404-2","volume":"14","author":"D Tan","year":"2013","unstructured":"Tan D, Chng WJ, Chou T, et al. Management of multiple myeloma in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14:571\u201381.","journal-title":"Lancet Oncol"},{"issue":"15","key":"8676_CR17","first-page":"538","volume":"12","author":"S Vincent","year":"2014","unstructured":"Vincent S, Rajkumar SV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology. 2014;12(15):538\u201348.","journal-title":"The Lancet Oncology"},{"issue":"25","key":"8676_CR18","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","volume":"116","author":"AJ Waxman","year":"2010","unstructured":"Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010;116(25):5501\u20136. https:\/\/doi.org\/10.1182\/blood-2010-07-298760.","journal-title":"Blood."},{"issue":"24","key":"8676_CR19","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1200\/JCO.2014.55.1028","volume":"32","author":"TM Wildes","year":"2014","unstructured":"Wildes TM, Rosko A, Tuchman SA. Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol. 2014;32(24):2531\u201340. https:\/\/doi.org\/10.1200\/JCO.2014.55.1028.","journal-title":"J Clin Oncol"},{"key":"8676_CR20","unstructured":"World Health Organization. The Global Health Observatory. Geneva: World Health Organization; Mulriple myeloma, Source Globocan 2020."},{"issue":"11","key":"8676_CR21","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.bbmt.2013.08.002","volume":"19","author":"LJ Costa","year":"2013","unstructured":"Costa LJ, Zhang MJ, Zhong X, et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant. 2013;19(11):1615\u201324. https:\/\/doi.org\/10.1016\/j.bbmt.2013.08.002.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"8676_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1471-2407-10-74","volume":"10","author":"C Renshaw","year":"2010","unstructured":"Renshaw C, Ketley N, M\u00f8ller H, Davies E. Trends in the incidence and survival of multiple myeloma in south East England 1985-2004. BMC Cancer. 2010;10(1):74. https:\/\/doi.org\/10.1186\/1471-2407-10-74.","journal-title":"BMC Cancer"},{"issue":"1","key":"8676_CR23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/1471-2407-14-438","volume":"14","author":"MS Hossain","year":"2014","unstructured":"Hossain MS, Iqbal MS, Khan MA, Rabbani MG, Khatun H, Munira S, et al. Diagnosed hematological malignancies in Bangladesh - a retrospective analysis of over 5000 cases from 10 specialized hospitals. BMC Cancer. 2014;14(1):438. https:\/\/doi.org\/10.1186\/1471-2407-14-438.","journal-title":"BMC Cancer"},{"issue":"1","key":"8676_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-019-0706-9","volume":"12","author":"W Liu","year":"2019","unstructured":"Liu W, Liu J, Song Y, et al. Mortality of lymphoma and myeloma in China, 2004-2017: an observational study. J Hematol Oncol. 2019;12(1):22\u20138. https:\/\/doi.org\/10.1186\/s13045-019-0706-9.","journal-title":"J Hematol Oncol"},{"key":"8676_CR25","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1182\/blood-2014-10-609461","volume":"125","author":"SR Philip","year":"2015","unstructured":"Philip SR, Kimberly A, et al. Future distribution of multiple myeloma in the United States by sex, age, and race\/ethnicity. Blood. 2015;125:410\u20132.","journal-title":"Blood."},{"key":"8676_CR26","first-page":"009584","volume":"6","author":"V Ram\u00f3n","year":"2016","unstructured":"Ram\u00f3n V, Ingemar T, Ola L, et al. Incidence of multiple myeloma in Great Britain, Sweden, and Malm\u00f6, Sweden: the impact of differences in case ascertainment on observed incidence trends. BMJ Open. 2016;6:009584.","journal-title":"BMJ Open"},{"issue":"10","key":"8676_CR27","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/bcj.2016.100","volume":"6","author":"A Ravindran","year":"2016","unstructured":"Ravindran A, Bartley AC, Holton SJ, et al. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J. 2016;6(10):486.","journal-title":"Blood Cancer J"},{"issue":"1","key":"8676_CR28","first-page":"20","volume":"1","author":"SP Santosh","year":"2012","unstructured":"Santosh SP, Patel D, R. Epidemiology, biology, and outcome in multiple myeloma patients in different geographical areas of the world. J Adv Intern Med. 2012;1(1):20\u201332.","journal-title":"J Adv Intern Med"},{"issue":"21","key":"8676_CR29","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Multiple myeloma (010) study investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123\u201332. https:\/\/doi.org\/10.1056\/NEJMoa070594.","journal-title":"N Engl J Med"},{"issue":"3","key":"8676_CR30","first-page":"5","volume":"1","author":"SS Daghbashyan","year":"2006","unstructured":"Daghbashyan SS, Amirkhanyan ES, Meliksetyan KH, Khachatryan ES. Epidemiology of leukemia and lymphoma in Armenia according to 1998-2006. Blood (Krov). 2006;1(3):5\u201311.","journal-title":"Blood (Krov)"},{"issue":"2","key":"8676_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/bjh.13537","volume":"171","author":"D Pulte","year":"2015","unstructured":"Pulte D, Jansen L, Castro FA, Emrich K, Katalinic A, Holleczek B, et al. Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. Br J Haematol. 2015;171(2):189\u201396. https:\/\/doi.org\/10.1111\/bjh.13537.","journal-title":"Br J Haematol"},{"key":"8676_CR32","unstructured":"Survival statistics for multiple myeloma- Canadian Cancer Society https:\/\/www.cancer.ca\/en\/cancer-information\/cancer-type\/multiple-myeloma\/prognosis-and-survival\/survivalstatistics\u2024"},{"issue":"S1","key":"8676_CR33","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1097\/01.HS9.0000567176.98783.9c","volume":"3","author":"V Ptushkin","year":"2019","unstructured":"Ptushkin V, Vinogradova O, Chernikov M, Kochkareva Y, Zherebtsova V, Kobzev Y, et al. Epidemiology of multiple myeloma (MM) in Moscow (Russia). HemaSphere. 2019;3(S1):976. https:\/\/doi.org\/10.1097\/01.HS9.0000567176.98783.9c.","journal-title":"HemaSphere."},{"issue":"9","key":"8676_CR34","first-page":"412","volume":"21","author":"H Jalaeikhoo","year":"2018","unstructured":"Jalaeikhoo H, Sharifzadeh M, Rajaeinejad M, Keyhani M, Zokaasadi M. Retrospective analysis of 345 multiple myeloma cases: an investigation from 2 institutions. Arch Iran Med. 2018;21(9):412\u20137.","journal-title":"Arch Iran Med"},{"issue":"9","key":"8676_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2147\/CMAR.S126136","volume":"22","author":"OC Nwabuko","year":"2017","unstructured":"Nwabuko OC, Igbigbi EE, Chukwuonye II, et al. Multiple myeloma in Niger Delta, Nigeria: complications and the outcome of palliative interventions. Cancer Manag Res. 2017;22(9):189\u201396.","journal-title":"Cancer Manag Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08676-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08676-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08676-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T06:05:42Z","timestamp":1629525942000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08676-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,21]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8676"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08676-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-50131\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,21]]},"assertion":[{"value":"28 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of Committee of Ethics of the Yerevan State Medical University (YSMU) (Yerevan, Armenia). The permission to access and use the data was received from the local board of Committee of Ethics of the Hematology Center. The permission to access the data was granted by the director of the Hematology center. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"941"}}